新型凝血酶生成分析仪评估危重肝病与非肝病患者的凝血状态
本研究使用新型凝血酶生成分析仪ST Genesia,对ISOC-2研究中凝血酶原时间延长的危重患者进行凝血酶生成检测,并加入血栓调节蛋白评估蛋白C活性。结果显示,尽管凝血酶原时间延长,肝病组48.0%和非肝病组60.7%的患者凝血酶生成参数在正常范围内;加入血栓调节蛋白后两组凝血酶生成分别降低34.5%和41.8%,而新鲜冰冻血浆输注对凝血酶生成无影响。
要点
- 凝血酶原时间延长的危重患者中,近半数肝病组凝血酶生成参数正常。
- 加入血栓调节蛋白后凝血酶生成降低,提示蛋白C抗凝活性影响。
- 新鲜冰冻血浆输注未改变凝血酶生成,提示其不改善凝血潜力。
核心结论
- 加入血栓调节蛋白的凝血酶生成检测能更全面评估凝血能力,提示危重肝病患者尽管常规凝血试验异常,止血仍处于平衡状态。
研究设计与样本
- 研究基于ISOC-2队列,纳入凝血酶原时间延长(高于参考范围3秒)的危重患者,使用ST Genesia分析仪及STG-Thromboscreen试剂检测凝血酶生成,分肝病组和非肝病组。
主要发现
- 肝病组48.0%和非肝病组60.7%的患者凝血酶生成参数在正常范围内,尽管凝血酶原时间延长。
- 加入血栓调节蛋白后,肝病组和非肝病组凝血酶生成分别降低34.5%和41.8%。
- 新鲜冰冻血浆输注对凝血酶生成无影响。
关键数值与推荐
- 凝血酶原时间延长定义为高于参考范围3秒。
- 凝血酶生成检测使用含中等浓度人组织因子±兔血栓调节蛋白的STG-Thromboscreen试剂。
临床怎么用
- 对于危重肝病患者,凝血酶原时间延长不一定反映出血风险增加,可考虑使用加入血栓调节蛋白的凝血酶生成检测评估凝血潜力。
- 新鲜冰冻血浆输注可能不改善凝血酶生成,应谨慎用于纠正凝血异常。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The liver synthesizes the majority of pro- and anti-coagulant and fibrinolytic proteins, and during liver dysfunction synthesis of these proteins is reduced. The end point of conventional hemostatic tests, such as the prothrombin time (PT), occurs when only 5% of thrombin generation (TG) has taken place and is not sensitive to the effects of natural anti-coagulants. The aim of this study was to determine whether TG in the presence of thrombomodulin (TM) provides more useful information about coagulation potential, in comparison to the PT. Analysis was performed on ST Genesia, a novel TG analyzer from Diagnostica Stago. TG was measured using STG-Thromboscreen, a reagent containing an intermediate concentration of human tissue factor (TF) ± rabbit TM to account for anti-coagulant protein C (PC) activity. Platelet-poor plasma (PPP) samples were from the Intensive Care Study of Coagulopathy-2 (ISOC-2), which recruited patients admitted to critical care with a prolonged PT (3 seconds above the reference range). Despite a prolonged PT, 48.0% and 60.7% of patients in the liver and non-liver groups had TG parameters within the normal range. Addition of TM reduced TG by 34.5% and 41.8% in the liver and non-liver groups, respectively. Interestingly, fresh frozen plasma (FFP) transfusion had no impact on TG. Measurement of TG with addition of TM provides a more informative assessment of coagulation capacity and indicates that hemostasis is balanced in patients with liver disease during critical illness, despite conventional tests suggesting that bleeding risk is increased.
引用
- Morrow GB, Beavis J, Harper S, et al. Coagulation status of critically ill patients with and without liver disease assessed using a novel thrombin generation analyzer. J Thromb Haemost. 2020. PMID: 32196929. doi:10.1111/jth.14802
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。